Modulation of wound healing in glaucoma surgery

Velde, Sarah Van de; Bergen, Tine Van; Vandewalle, Evelien; Moons, Lieve; Stalmans, Ingeborg

doi:10.1016/bs.pbr.2015.05.002

Cited by 18 publications

(14 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…α-SMA is an indicator for myofibroblasts, whereas synthesis of fibronectin as a component of the ECM is increased in myofibroblasts, in comparison to fibroblasts. It was already confirmed that TGF-β is expressed in primary human ocular fibroblasts subpopulations [4], and that it plays a key role in ocular wound healing and scarring processes [53]. Following incubation of hTFs with TGF-β1, we confirmed increase in α-SMA and fibronectin expression, indicating fibroblast transformation into fibrotic active myofibroblasts.…”

Section: Discussionsupporting

confidence: 64%

Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblasts in vitro

et al. 2020

View full text Add to dashboard Cite

To elucidate and to inhibit post-surgical fibrotic processes after trabeculectomy in glaucoma therapy, we measured gene expression in a fibrotic cell culture model, based on transforming growth factor TGF-β induction in primary human tenon fibroblasts (hTFs), and used Connectivity Map (CMap) data for drug repositioning. We found that specific molecular mechanisms behind fibrosis are the upregulation of actins, the downregulation of CD34, and the upregulation of inflammatory cytokines such as IL6, IL11 and BMP6 . The macrolide antibiotic Josamycin (JM) reverses these molecular mechanisms according to data from the CMap, and we thus tested JM as an inhibitor of fibrosis. JM was first tested for its toxic effects on hTFs, where it showed no influence on cell viability, but inhibited hTF proliferation in a concentration-dependent manner. We then demonstrated that JM suppresses the synthesis of extracellular matrix (ECM) components. In hTFs stimulated with TGF-β1, JM specifically inhibited α-smooth muslce actin expression, suggesting that it inhibits the transformation of fibroblasts into fibrotic myofibroblasts. In addition, a decrease of components of the ECM such as fibronectin, which is involved in in vivo scarring, was observed. We conclude that JM may be a promising candidate for the treatment of fibrosis after glaucoma filtration surgery or drainage device implantation in vivo .

show abstract

Section: Discussionsupporting

confidence: 64%

Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblasts in vitro

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For example, collagen and elastin fiber characteristics of filtering blebs may possibly be useful to estimate filtering function and may be a predictor for encapsulation and subsequent failure. 28 Collagen and elastin fiber architecture and density at pterygium resection margins may also be used to monitor signs of early recurrence. 29 Finally, the potential to diagnose invasive corneal or conjunctival epithelial neoplasms that can destroy underlying collagen architecture may be another valuable clinical application of TPEM technology.…”

Section: Discussionmentioning

confidence: 99%

Details of the Collagen and Elastin Architecture in the Human Limbal Conjunctiva, Tenon's Capsule and Sclera Revealed by Two-Photon Excited Fluorescence Microscopy

Park

Marando

Liao

et al. 2016

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…If two of the above treatments fail, surgery may be considered to reduce the lower IOP. Various surgical options include glaucoma filtration surgery (trabeculectomy), glaucoma tube surgeries, and more recent minimally invasive glaucoma surgeries (MIGS) [ 29 , 30 , 31 , 32 ]. Filtration surgery creates a channel through which the aqueous humor can be drained through bleb formation [ 22 , 30 , 33 ].…”

Section: Glaucoma Treatmentmentioning

confidence: 99%

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

et al. 2020

View full text Add to dashboard Cite

Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients’ non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.

show abstract

Modulation of wound healing in glaucoma surgery

Cited by 18 publications

References 121 publications

Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblasts in vitro

Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblasts in vitro

Details of the Collagen and Elastin Architecture in the Human Limbal Conjunctiva, Tenon's Capsule and Sclera Revealed by Two-Photon Excited Fluorescence Microscopy

Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Contact Info

Product

Resources

About